$3.5 Billion Covetrus-MWI Deal Faces FTC Scrutiny Ahead of Closing
Key Facts
There is no reliable public confirmation that the U.S. Federal Trade Commission plans to sue on Friday, Nov. 13, 2026, to block the $3.5 billion Covetrus-MWI Animal Health deal. But the transaction has already faced FTC scrutiny: Cencora received a request for additional information and documents about the merger on May 20, 2026, according to its filing with the U.S. Securities and Exchange Commission. That means the regulatory review is underway, while talk of a lawsuit on that date remains unconfirmed. Bloomberg Law reported that the commission's requests addressed the deal's effect on the availability of veterinary products and practice-management software. The available information did not confirm that these issues led to a decision to sue.
Bloomberg Law described the proposed deal as a $3.5 billion acquisition bringing together two of the leading national suppliers of veterinary products in the United States. The transaction aims to combine distribution of companion-animal and production-animal health products with technology platforms, according to Covetrus's description of the proposed combination. The merger would bring distribution networks and software within the scope of the deal, while the FTC's inquiries, according to Bloomberg Law, focused on product availability and practice-management software. Required regulatory approvals remain among the customary conditions to closing, according to Covetrus. The prior scrutiny alone therefore does not establish that the deal will be blocked or that legal action has been taken.
Under the deal terms announced by Cencora, the company will receive $1.25 billion in cash, $800 million in preferred stock and $1.45 billion in common stock at closing. Those components total $3.5 billion, divided between cash and equity instruments in the combined company. Covetrus said Cencora's common-stock stake after closing will be 34.3%, leaving it with a noncontrolling interest. The terms would give Cencora cash consideration alongside stakes in the resulting entity, without granting it control under the announced arrangement. That consideration remains contingent on closing and satisfaction of the deal's conditions.
In its fiscal 2027 outlook, Cencora assumed that the MWI Animal Health-Covetrus merger would close on March 31, 2027. Its fiscal 2026 guidance, for the year ended Sept. 30, 2026, did not assume the deal would close before the end of that year. The timeline separates the earlier fiscal 2026 estimate from the date the company is using in its outlook for the following year. Covetrus said closing is subject to customary conditions, including obtaining required regulatory approvals. Cencora's assumed date in its outlook does not change the fact that closing depends on completing those requirements.